spacer
home > ebr > winter 2002 > truncate rna preparation in crna labelling reactions without sacrificing microarray performance?
PUBLICATIONS
European Biopharmaceutical Review

Truncate RNA Preparation in cRNA Labelling Reactions Without Sacrificing Microarray Performance?

When preparing cRNA samples for microarray analysis, researchers must choose between mRNA and total RNA as the starting material for labelling. The method of choice for high quality mRNA preparation typically involves total RNA extraction followed by an additional step of mRNA purification. While this method generally yields high quality substrates for microarray target preparation, its major drawback is the addition of an extra step to the preparation process which increases the amount of product lost by approximately 30% and also increases the potential for sample degradation, both of which result in lower amplified cRNA yields and decreased microarray sensitivity. In light of these issues, microarray researchers have recently developed protocols to improve the feasibility of using total RNA directly in the labelling reaction.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Jenny Xiao, Applications Scientist at Agilent Technologies Dr Jenny Xiao obtained her PhD in Molecular Genetics at the University of Hawaii in 1997. Her dissertation focused on gene cloning, differential gene expression and the characterisation of the molecular basis for white-eye mutation in the Oriental fruit fly.
Subsequently, Jenny became a postdoctoral fellow at Stanford University, using microarray to perform apoptosis studies that identified redox and mitochondrial elements which control resistance or sensitivity to cell death. She is currently an Applications Scientist at Agilent Technologies, working on its gene expression solutions platform.

spacer
Dr Jenny Xiao
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Drive for generics sees Korea increasingly attractive to international pharma

Amsterdam, 31st July 2019: Already home to more than 40 pharmaceutical multinationals, Korea is on course to become a global biotech and pharmaceutical hub by 2025, driven by the surge of international partnerships, biosimilars, an expansion in the export of finished formulations and a robust generics market.
More info >>

White Papers

Faster, Better, Cheaper: Lean as a Driving Force Behind Pharmaceutical Companies’ Growth

TBM Consulting Group

The pharmaceutical industry faces countless challenges: patent expirations, weak product development pipelines, downward pricing pressure and an increasingly burdensome regulatory environment. The most important question for companies is now “How can we position ourselves optimally to be successful in the long term?” Some pharmaceutical companies used the economic downturn in 2009 to embrace measures in the fields of cost reduction and efficiency increases, which can be implemented at short notice. The continuous and consistent implementation of sustainable measures that guarantee stability and form the basis for future growth was not necessarily paramount within this.
More info >>

 
Industry Events

ELRIG Drug Discovery 2019 – Looking Back to the Future

5-6 November 2019, ACC, Liverpool

Now in its 13th year, ELRIG’s flagship conference Drug Discovery 2019 will take place at ACC in Liverpool. This year’s focus, ‘A Look Back to the Future’ is planned to include plenary introductions assessing how we got to where we are now and setting the challenges for discovering the drugs of the future. These will be followed by cutting edge talks and examples of new directions in drug discovery. Our scientific programme will feature over 40 world-class speakers with 6 main session tracks. In partnership with key academic and charitable groups, we will also run joint disease and biology-oriented tracks focusing on the basic sciences that underpin successful drug discovery.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement